Efficacy of Trimebutine Combined with Mosapride on Functional Dyspepsia

Objective To evaluate the efficacy and safety of trimebutine combined with mosapride on functional dyspepsia. Methods Patients with functional dyspepsia were randomly divided into three clinical groups. Group A( n = 116)received 0. 2 g trimebutine after meal,group the drug combination B( n = 116) received 5 mg mosapride before meal,and the drug combination group( n = 115) received 0. 2 g trimebutine after meal plus 5 mg mosapride before meal. All medications were taken orally three times daily for 4 weeks. Improvement in clinical symptoms and adverse reactions in each group were evaluated at the end of study. Results A total of 339 patients among 347 enrollees completed the treatment and follow-up. The clinical efficacy on postprandial fullness,early satiation,epigastric pain,epigastric burning,upper abdominal bloating and nausea were88. 4%,76. 9%,72. 9%,61. 8%,86. 7% and 81. 7%,respectively in the drug combination group after 4-week treatment,which were superior to those in group A or B( P 0. 05) except for epigastric burning. The total effective rate of the drug combination group was 78. 8%,significantly higher than the other two groups( P 0. 05). The total incidence of side effects in the drug combination group was 1. 8%,similar to that of group A and B( 1. 8% and 0. 9%,respectively,P = 0. 776). Conclusion Trimebutine combined with mosapride is safe and effective for improving symptoms in functional dyspepsia.